Multicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancer.
- Author:
Jin Soo KIM
1
;
Ji Yeon KIM
;
Sang Jeon LEE
;
Dong Kook PARK
;
Hwan NAMGUNG
;
Chang Nam KIM
;
Won Jun CHOI
;
Moo Jun BAEK
Author Information
- Publication Type:Multicenter Study ; Original Article
- Keywords: Vomiting; Ramosetron; Palonosetron; Adjuvant chemotherapy; Colorectal neoplasms
- MeSH: Administration, Oral; Chemotherapy, Adjuvant; Colorectal Neoplasms*; Drug Therapy; Humans; Incidence; Injections, Intravenous; Nausea*; Quality of Life; Receptors, Serotonin, 5-HT3; Serotonin; Vomiting*
- From:Annals of Surgical Treatment and Research 2014;87(1):9-13
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Chemotherapy-induced nausea and vomiting (CINV) have a negative impact on patients' quality of life and frequently pointed to as a major factor for treatment abandonment. Serotonin (5-HT3) receptor antagonist is considered as key treatment for CINV. Ramosetron and palonosetron are recently developed 5-HT3 receptor antagonists and known as more superior than other first-generation 5-HT3 receptor antagonists. The purpose of this study was to compare the efficacy of ramosetron and palonosetron and determine which drug is more effective for prevention of CINV. METHODS: Colorectal cancer patients treated with chemotherapy were enrolled consecutively. Patients were assigned to receive intravenous injection of ramosetron 0.3 mg or palonosetron 0.25 mg at 30 minutes before initiation of moderately emetogenic chemotherapy. Ramosetron group added oral administration of 0.1 mg ramosetron on the second and third days of chemotherapy. Efficacy parameter consisted of nausea and vomiting. RESULTS: Ninety-one patients received ramosetron and 89 patients received palonosetron. Presentation of vomiting and nausea symptoms was not significantly different between the two groups during acute (0-24 hours) and delayed period (after 24 hours). CONCLUSION: The incidence of CINV between the ramosetron and the palonosetron group has not shown any difference during acute, delayed, and overall period.
